SCHEMBL23042404

SCHEMBL23042404

COc1nc2ccc(Br)cc2n1C1(C(F)F)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPM1 P06748 2/20 0.38
ALK Q9UM73 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
ACACB O00763 2/20 0.34
TSPO P30536 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
OPRM1 P35372 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
GLP1R P43220 1/20 0.32
PDE2A O00408 1/20 0.32
PDE10A Q9Y233 1/20 0.32
PRNP P04156 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29612462 1.00 NPM1 (0.38) NPM1ALKMEN1KMT2ASMN1; SMN2
SCHEMBL29729434 0.84 CYP11B1 (0.34) PIK3CDPIK3CAPIK3CB
SCHEMBL29729431 0.84 CYP11B1 (0.34) PIK3CDPIK3CAPIK3CB
SCHEMBL23062845 0.82 MEN1 (0.40) NPM1ALKMEN1KMT2ASMN1; SMN2
SCHEMBL23042368 0.74 MTNR1A (0.32) PIK3CDPIK3CAPIK3CB
SCHEMBL15112680 0.72 MAPT (0.55) NPM1ALKMEN1KMT2ASMN1; SMN2
SCHEMBL29729492 0.72 MAPT (0.55) NPM1ALKMEN1KMT2ASMN1; SMN2
SCHEMBL20987182 0.72 MAPT (0.42) NPM1ALKMEN1KMT2ASMN1; SMN2
SCHEMBL29729386 0.72 MAPT (0.42) NPM1ALKMEN1KMT2ASMN1; SMN2
SCHEMBL23042385 0.71 MAPT (0.35) MEN1KMT2ASMN1; SMN2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528791-B2 Thyroid hormone receptor beta agonist compounds TERNS PHARMACEUTICALS, INC. (US) 2026-01-20 US disclosed
US-20240059682-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS PHARMACEUTICALS, INC. 2024-02-22 US disclosed
EP-4301357-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns Pharmaceuticals, Inc. (US) 2024-01-10 EP disclosed
CN-117120051-A Thyroid hormone receptor beta agonist compounds 拓臻制药公司 2023-11-24 CN disclosed
WO-2022187403-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS PHARMACEUTICALS, INC. (US) 2022-09-09 WO disclosed
US-20220281849-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS PHARMACEUTICALS, INC. 2022-09-08 US disclosed
EP-4017875-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns Pharmaceuticals, Inc. (US) 2022-06-29 EP disclosed
CN-114430743-A Thyroid hormone receptor beta agonist compounds 拓臻制药公司 2022-05-03 CN disclosed
WO-2021041237-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. (US) 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528791-B2 Thyroid hormone receptor beta agonist compounds THRB, THRA, TSHR NPM1 4508/4885ALK 723/4885MEN1 866/4885
US-20220281849-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS THRB, THRA, TSHR NPM1 4865/4885ALK 1533/4885MEN1 1016/4885
US-20240059682-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS THRB, THRA, TSHR NPM1 4865/4885ALK 1772/4885MEN1 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.